Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 8 de 8
Filter
1.
Arch Argent Pediatr ; 120(1): e49-e53, 2022 02.
Article in Spanish | MEDLINE | ID: mdl-35068131

ABSTRACT

Tumor lysis syndrome is a potentially lethal complication and constitutes with infections the most frequent oncological emergency. In children, this condition can be secondary to neoplastic diseases, with corticosteroids being a triggering factor. This paper presents the case of an adolescent patient, without known or obvious neoplasms, who developed a tumor lysis syndrome after the administration of corticosteroids due to suspected respiratory infection. The clinical presentation and differential diagnoses are discussed. Special focus is placed on the administration of corticosteroids in clinical conditions with weak scientific evidence. The use of systemic corticosteroids in acute respiratory infections should be evaluated in the clinical context and only indicated in situations with proven effectiveness.


El síndrome de lisis tumoral es una complicación potencialmente letal y constituye, junto con las infecciones, la emergencia oncológica más frecuente. En pediatría, este cuadro puede ser secundario a enfermedades neoplásicas, y los corticoides son un factor desencadenante. En este trabajo se presenta el caso de una paciente adolescente, sin neoplasias conocidas o evidentes, que desarrolló un síndrome de lisis tumoral luego de la administración de corticoides por sospecha de una infección respiratoria. Se discute la forma de presentación y los diagnósticos diferenciales del cuadro clínico inicial. Se hace especial foco en la administración de corticoides en cuadros clínicos en los que no existe evidencia científica que respalde fuertemente su indicación. El uso de corticosteroides sistémicos en infecciones respiratorias agudas debe ser evaluado en el contexto clínico y solo debe indicarse en situaciones con probada efectividad.


Subject(s)
Tumor Lysis Syndrome , Adolescent , Adrenal Cortex Hormones/adverse effects , Child , Humans , Tumor Lysis Syndrome/diagnosis , Tumor Lysis Syndrome/etiology
2.
Pediatr Infect Dis J ; 40(9): e340-e343, 2021 09 01.
Article in English | MEDLINE | ID: mdl-34288632

ABSTRACT

AIM: To describe a term newborn with acquired severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection and multisystem involvement including seizures associated to ischemic lesions in the brain. BACKGROUND: Coronavirus disease 2019 (COVID-19) is predominantly a respiratory infection, but it may affect many other systems. Most pediatric COVID-19 cases range from asymptomatic to mild-moderate disease. There are no specific clinical signs described for neonatal COVID-19 infections. In children, severe central nervous system compromise has been rarely reported. CASE DESCRIPTION: We describe a 17-day-old newborn who acquired a SARS-CoV-2 infection in a family meeting that was admitted for fever, seizures and lethargy and in whom consumption coagulopathy, ischemic lesions in the brain and cardiac involvement were documented. CONCLUSIONS: SARS-CoV-2 neonatal infection can be associated with multi-organic involvement. In our patient, significant central nervous system compromise associated to ischemic lesions and laboratory findings of consumption coagulopathy were found. CLINICAL SIGNIFICANCE: Although neonatal SARS-CoV-2 infections are infrequent, they can be associated with multi-organic involvement. Neonatologists and pediatricians should be aware of this unusual way of presentation of COVID-19 in newborn infants.


Subject(s)
Brain Ischemia/virology , COVID-19/complications , Infant, Newborn, Diseases/virology , SARS-CoV-2/isolation & purification , Acyclovir/therapeutic use , Anti-Bacterial Agents/therapeutic use , Antiviral Agents/therapeutic use , Brain/diagnostic imaging , Brain Ischemia/pathology , COVID-19/pathology , Ceftriaxone/therapeutic use , Fever , Frontal Lobe/blood supply , Frontal Lobe/diagnostic imaging , Frontal Lobe/pathology , Humans , Infant, Newborn , Infant, Newborn, Diseases/drug therapy , Infant, Newborn, Diseases/pathology , Lethargy , Magnetic Resonance Imaging , Male , Nasopharynx/virology , Seizures , COVID-19 Drug Treatment
3.
Pediatr Blood Cancer ; 52(4): 491-6, 2009 Apr.
Article in English | MEDLINE | ID: mdl-19058214

ABSTRACT

BACKGROUND: Demographics, outcome, and management of idiopathic thrombocytopenic purpura (ITP) in children present differences between countries. Although several factors influence outcome, it is impossible to predict at diagnosis which patients will have acute or chronic disease. High rates of spontaneous remission in chronic ITP have been reported. PROCEDURE: Data concerning 1,683 patients with ITP diagnosed from 1981 to date are presented; outcome was evaluated in 1,418 children. RESULTS: Remarkable presenting features were an incidence peak in the first 2 years of age and male predominance in patients <24 months of age. Three age groups with different recovery rates (P < 0.001) were established (2-12 months: 89.8%; 1-8 years: 71.3%; 9-18 years: 49.0%). Platelet count <10 x 10(9)/L and history of previous illness were associated with higher remission rates only in patients >12 months of age. The score developed by the NOPHO Group showed a predictive value of 83.9% for acute ITP. Spontaneous remission between 6 months and 11 years from diagnosis was achieved by 107 of 325 (32.9%) non-splenectomized children with chronic ITP, and in 44.9% of them between 6 and 12 months from diagnosis. CONCLUSIONS: Age and score were main prognostic factors. Infants <1 year of age are a special group with a brief course and very high recovery rate that are not influenced by other prognostic factors. Definition of groups based on age and scoring could be useful to establish differential management guidelines. The cut-off value to define chronic ITP should be changed to 12 months.


Subject(s)
Purpura, Thrombocytopenic, Idiopathic/epidemiology , Purpura, Thrombocytopenic, Idiopathic/physiopathology , Adolescent , Age Distribution , Argentina/epidemiology , Child , Child, Preschool , Demography , Female , Humans , Incidence , Infant , Male , Prognosis , Sex Distribution
4.
Arch. argent. pediatr ; 120(1): e49-e53, feb 2022. tab, ilus
Article in Spanish | LILACS, BINACIS | ID: biblio-1353830

ABSTRACT

El síndrome de lisis tumoral es una complicación potencialmente letal y constituye, junto con las infecciones, la emergencia oncológica más frecuente. En pediatría, este cuadro puede ser secundario a enfermedades neoplásicas, y los corticoides son un factor desencadenante. En este trabajo se presenta el caso de una paciente adolescente, sin neoplasias conocidas o evidentes, que desarrolló un síndrome de lisis tumoral luego de la administración de corticoides por sospecha de una infección respiratoria. Se discute la forma de presentación y los diagnósticos diferenciales del cuadro clínico inicial. Se hace especial foco en la administración de corticoides en cuadros clínicos en los que no existe evidencia científica que respalde fuertemente su indicación. El uso de corticosteroides sistémicos en infecciones respiratorias agudas debe ser evaluado en el contexto clínico y solo debe indicarse en situaciones con probada efectividad.


Tumor lysis syndrome is a potentially lethal complication and constitutes with infections the most frequent oncological emergency. In children, this condition can be secondary to neoplastic diseases, with corticosteroids being a triggering factor. This paper presents the case of an adolescent patient, without known or obvious neoplasms, who developed a tumor lysis syndrome after the administration of corticosteroids due to suspected respiratory infection.The clinical presentation and differential diagnoses are discussed. Special focus is placed on the administration of corticosteroids in clinical conditions with weak scientific evidence. The use of systemic corticosteroids in acute respiratory infections should be evaluated in the clinical context and only indicated in situations with proven effectiveness.


Subject(s)
Humans , Female , Adolescent , Tumor Lysis Syndrome/diagnosis , Tumor Lysis Syndrome/etiology , Adrenal Cortex Hormones/adverse effects
5.
Rev. am. med. respir ; 14(3): 318-322, set. 2014. ilus
Article in Spanish | LILACS | ID: lil-734444

ABSTRACT

El Tumor Carcinoide es un tipo de tumor cancerígeno formado por células neuroendocrinas. Representa el 1 al 2% de todos los tumores. En el pasado, fueron agrupados en una categoría de neoplasias denominada adenomas bronquiales. Se los consideraba benignos o poco agresivos. Se clasifican según su ubicación en centrales y periféricos y de acuerdo a su histología, dependiendo del número de mitosis y la presencia o no de necrosis, en típicos y atípicos. Tienen una gran variedad de presentación clínica, con diferentes grados de agresividad y pronóstico. Generalmente su diagnóstico es tardío. Nuestro objetivo fue presentar un caso pediátrico de Tumor Carcinoide pulmonar, central y típico.


The pulmonary carcinoid tumor (CT) is a type of cancerous tumor composed of neuroendocrine cells. It represents 1 or 2% of all pulmonary tumors. In the past, these tumors were grouped into a category of neoplasias called bronchial adenomas. They are considered benign or little aggressive. They are classified in central and peripheral tumors depending on their location and in histologic typical and atypical tumors depending on the number of mitosis and the presence or absence of necrosis. They have a wide variety of clinical presentation, with different degrees of aggressiveness and prognosis. The diagnosis is usually late. Our purpose was to present a pediatric case of central and typical pulmonary carcinoid tumor.


Subject(s)
Carcinoid Tumor , Carcinoma, Neuroendocrine
6.
Pediatr Blood Cancer ; 47(5 Suppl): 737-9, 2006 Oct 15.
Article in English | MEDLINE | ID: mdl-16933257

ABSTRACT

Two hundred thirty of 696 evaluable children were identified as having chronic idiopathic thrombocytopenic purpura (ITP). Splenectomy was performed in 30 (13%), achieving remission in 22 (73%). Favorable response was associated to higher initial platelet count. Spontaneous remission was achieved by 53/200 non-splenectomized patients (26.5%), up to 10 years from diagnosis. More than half of them recovered between 6th and 12th month from diagnosis. The recovery rate was significantly higher (P=0.03) in children aged<9 years (31.2%) than in older children (14.6%). No reliable factor predictive of response in individual cases is still available.


Subject(s)
Outcome Assessment, Health Care , Purpura, Thrombocytopenic, Idiopathic/surgery , Splenectomy , Adolescent , Age Factors , Child , Child, Preschool , Chronic Disease , Databases, Factual , Follow-Up Studies , Humans , Infant , Platelet Count , Purpura, Thrombocytopenic, Idiopathic/diagnosis , Remission Induction , Remission, Spontaneous , Treatment Outcome
SELECTION OF CITATIONS
SEARCH DETAIL